109 related articles for article (PubMed ID: 38103327)
21. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer.
Ring AE; Smith IE; Ashley S; Fulford LG; Lakhani SR
Br J Cancer; 2004 Dec; 91(12):2012-7. PubMed ID: 15558072
[TBL] [Abstract][Full Text] [Related]
22. Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy.
Morgan DA; Refalo NA; Cheung KL
Breast; 2011 Jun; 20(3):215-9. PubMed ID: 21159509
[TBL] [Abstract][Full Text] [Related]
23. Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis.
Chen T; Zhang N; Moran MS; Su P; Haffty BG; Yang Q
Clin Breast Cancer; 2018 Feb; 18(1):1-8. PubMed ID: 28712925
[TBL] [Abstract][Full Text] [Related]
24. Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility.
Kumegawa K; Saeki S; Takahashi Y; Yang L; Osako T; Nakadai T; Amino S; Maeda T; Takahata C; Mori S; Noda T; Ohno S; Ueno T; Maruyama R
Br J Cancer; 2023 Mar; 128(7):1208-1222. PubMed ID: 36725920
[TBL] [Abstract][Full Text] [Related]
25. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
[TBL] [Abstract][Full Text] [Related]
27. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
28. Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level.
Atallah NM; Alsaleem M; Toss MS; Mongan NP; Rakha E
Br J Cancer; 2023 Nov; 129(10):1692-1705. PubMed ID: 37740038
[TBL] [Abstract][Full Text] [Related]
29. Contribution of endocrine therapy in oestrogen receptor-positive pT1a-b breast cancer: Results of a retrospective study.
Houvenaeghel G; de Nonneville A; Cohen M; Classe JM; Reyal F; Mazouni C; Faure C; Martinez A; Chauvet MP; Daraï E; Coutant C; Colombo PE; Gimbergues P; Azuar AS; Rouzier R; Tunon de Lara C; Crochet P; Rua S; Gonçalves A
Eur J Cancer; 2022 Nov; 176():58-69. PubMed ID: 36194904
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of PDEF factor expression and its relation to androgen receptor in ER
Cao L; Li C; Xu C; Xiang G; Liu F; Liu X; Jiao J; Lv S; Niu Y
Histopathology; 2018 Nov; 73(5):819-831. PubMed ID: 29969155
[TBL] [Abstract][Full Text] [Related]
31. Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.
Joseph C; Al-Izzi S; Alsaleem M; Kurozumi S; Toss MS; Arshad M; Goh FQ; Alshankyty IM; Aleskandarany MA; Ali S; Ellis IO; Mongan NP; Green AR; Rakha EA
Br J Cancer; 2019 Oct; 121(9):776-785. PubMed ID: 31558802
[TBL] [Abstract][Full Text] [Related]
32. The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long-term follow-up.
Lashen AG; Toss MS; Mongan NP; Green AR; Rakha EA
Cancer; 2023 Apr; 129(8):1183-1194. PubMed ID: 36653923
[TBL] [Abstract][Full Text] [Related]
33. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322
[TBL] [Abstract][Full Text] [Related]
34. Impact of Androgen Receptor Expression and the AR:ER Ratio on the Survival Outcomes in the Diverse Subgroups of Vietnamese Breast Cancer: A Single Institutional Retrospective Cohort Analysis.
Phung HT; Nguyen CV; Mai NT; Vu HTN; Pham KH; Tran GL
Technol Cancer Res Treat; 2022; 21():15330338221080941. PubMed ID: 35379053
[No Abstract] [Full Text] [Related]
35. Clinicopathological Features and Survival for Low ER-positive Breast-cancer Patients.
He A; Zhou T
Altern Ther Health Med; 2022 Sep; 28(6):36-41. PubMed ID: 35648695
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
[TBL] [Abstract][Full Text] [Related]
37. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
[TBL] [Abstract][Full Text] [Related]
38. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group.
Ahmed SS; Thike AA; Zhang K; Lim JC; Tan PH
J Clin Pathol; 2017 Apr; 70(4):320-326. PubMed ID: 27612503
[TBL] [Abstract][Full Text] [Related]
40. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
